Modern treatment of chronic myeloid leukemia
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 12
- DOI:
- 10.3760/cma.j.issn.1009-9921.2009.12.001
- Key Word:
- 白血病;髓样;慢性;酪氨酸激酶抑制剂;融合蛋白质类;bcr-abl;点突变;Leukemia myeloid;chronic;Tyrosine kinase inhibitors;Fusion proteins;bcr-abl;Point mutation
Abstract： Imatinib and the second generation tyrosine kinase inhibitors(TKI) not only have revolutionized the management of patients with CML,but also become a model for the development of novel targeting agents in treating malignancies. Under IM treatment.more than 90%CML-CP patients could achieve complete hematologic remission,and more than 80% patients could achieve CCyR/MMoR.,the event free survival at 6-7 years were around 80%.resulting in a major change in the natural history of CML.Nevetherless, TKI cannot eliminate the bcr-abl fusion gene or CML stem cells.the patients have to take the medicine continuously or for life long,More than 10%patients developing resistance Or intolerance are also problematic.The available TKI are preferable choice for treatment of CML
- [1]秦亚溱,刘艳荣,李金兰,等.慢性髓性白血病患者伊马替尼治疗后ABL激酶区点突变分析[J].2005,(45).
- [2]Krahnke T,Gathmann I,Wang Y,etc.Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.[J].2008,111(8).
- [3]Olavarria E,Pavlu J,Reid AG,etc.European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.[J].2008,112(12).
- [4]Bleickardt E,Milone JH,Paquette RL,etc.Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.[J].2008,26(19).
- [5]Gontarewicz A,Balabanov S,Graziano A,etc.Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.[J].2008,111(8).
- [6]Khorashad JS,Kaeda J,Reid AG,etc.Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.[J].2008,26(20).
- [7]Muller MC,Radich J,Hochhaus A.Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.[J].2009,23(9).
- [8]Krahnke T,Cortes J,Sawyers C,etc.Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.[J].2008,111(3).
- [9]O'Brien S,Cortes JE,Quintas Cardama A.Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.[J].2009,115(13).
- [10]Roy L,Corm S,Silver RT,etc.Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.[J].2008,22(6).
- [11]Kantarjian H,Giles F,Wunderle L,etc.Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.[J].2006,354(24).
- [12]Seymour JF,Filshie R,Branford S,etc.Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.[J].2008,112(10).
- [13]O'Brien S,Garcia-Manero G,Jabbour E,etc.Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.[J].2008,112(1).
- [14]Kantarjian H,Powell BL,Cervantes F,etc.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.[J].2006,355(23).